NEW YORK (GenomeWeb) – The US Food and Drug Administration and the Centers for Medicare & Medicaid Services presented a unified front before Congress today, making the case that the FDA needs to play a leading role in evaluating the safety and efficacy of laboratory-developed tests (LDTs) and that CMS doesn't have the expertise or resources to take up the task as some in the lab and pathology community have suggested.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.